Aptar Committed to Increasing Investment in India to Meet Growing Needs of Pharma Industry
Aptar continues expansion with additional pharma plant near Mumbai, India Sanjay Kapote, President of Aptar Pharma India and Southeast Asia Crystal Lake, Illinois : AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the groundbreaking ceremony of its new pharma plant in Taloja, India, near Mumbai. The facility will help Aptar continue to meet the growing demands of the pharmaceutical industry in India. Sanjay Kapote, President of Aptar Pharma India and Southeast Asia, commented, “Over the past decade, Aptar Pharma has achieved strong and consistent growth, thanks to our reliable products, regulatory expertise and knowledge of patient needs. This additional plant in Taloja will further strengthen our ability to efficiently deliver high-quality, innovative products and reinforces our commitment to investing in the pharma end markets. Additionally, we are keen on exploring acquisitions in the pharma space. We see significant growth potential within the pharmaceutical industry in India and the potential to expand our position in the market.” The new state-of-the-art facility will expand the company’s existing footprint in the region while adding additional local production of several technologies including Aptar’s pressurized metered-dose inhaler (pMDI) valve, as well as breath-actuated devices and single-dose nasal sprays. The new Taloja plant will also enable Aptar to meet the region’s growing needs by adding an additional 4400 m2 of manufacturing footprint and will be constructed adjacent to the existing Aptar Mumbai facility that opened in 2023. Aptar is committed to strengthening its roots in the region through both organic growth and strategic acquisitions. The company looks for potential acquisitions and partnerships with IP driven, pharma packaging companies to continue the expansion of their drug dosing, dispensing and protection offerings. About Aptar Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com. This press release contains forward-looking statements. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law. Aptar Investor Relations Contact: Mary Skafidas mary.skafidas@aptar.com +1 347 351 6407 Aptar Media Contact Katie Reardon katie.reardon@aptar.com +1 815 479 5671 For further media queries, please contact: Sonia Kulkarni, Hunk G
Sanjay Kapote, President of Aptar Pharma India and Southeast Asia
Crystal Lake, Illinois : AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the groundbreaking ceremony of its new pharma plant in Taloja, India, near Mumbai. The facility will help Aptar continue to meet the growing demands of the pharmaceutical industry in India.
Sanjay Kapote, President of Aptar Pharma India and Southeast Asia, commented, “Over the past decade, Aptar Pharma has achieved strong and consistent growth, thanks to our reliable products, regulatory expertise and knowledge of patient needs. This additional plant in Taloja will further strengthen our ability to efficiently deliver high-quality, innovative products and reinforces our commitment to investing in the pharma end markets. Additionally, we are keen on exploring acquisitions in the pharma space. We see significant growth potential within the pharmaceutical industry in India and the potential to expand our position in the market.”
The new state-of-the-art facility will expand the company’s existing footprint in the region while adding additional local production of several technologies including Aptar’s pressurized metered-dose inhaler (pMDI) valve, as well as breath-actuated devices and single-dose nasal sprays.
The new Taloja plant will also enable Aptar to meet the region’s growing needs by adding an additional 4400 m2 of manufacturing footprint and will be constructed adjacent to the existing Aptar Mumbai facility that opened in 2023.
Aptar is committed to strengthening its roots in the region through both organic growth and strategic acquisitions. The company looks for potential acquisitions and partnerships with IP driven, pharma packaging companies to continue the expansion of their drug dosing, dispensing and protection offerings.
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.
This press release contains forward-looking statements. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Forms 10-Q. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
Aptar Investor Relations Contact:
Mary Skafidas
+1 347 351 6407
Aptar Media Contact
Katie Reardon
+1 815 479 5671
For further media queries, please contact:
Sonia Kulkarni, Hunk Golden and Media
Mobile: 9820184099 | Email: sonia.kulkarni@hunkgolden.in
